Impact of early-stage immunotherapy on health and work productivity in the Czech Republic, 2024-2033.

Key Points

• The aim is to assess the impact of early-stage immunotherapy on health and work productivity in the Czech Republic.
• Evaluation of the use of anti-PD-(L)1 agents in early-stage cancer treatment.
• Analysis of outcomes related to health and work productivity.
• Assessment of quality-of-life and survival rates.
• Early-stage immunotherapy is expected to reduce events and recurrences.
• Innovative immunotherapy extends survival and enhances quality-of-life.
• Increased productive work years contribute to societal value.